Tessera
Folgen

John Ebos

@ebos.bsky.social

Associate Prof. in Cancer Genetics at Roswell Park Comprehensive Cancer Center studying drug resistance, metastasis, the tumor microenvironment, immunecheckpoints, and angiogenesis. https://www.roswellpark.org/research/labs/ebos-lab

87 Posts1432 Follower1757 Folgt
Nikolai Slavov@slavov-n.bsky.social · last mo.

Since the 1960s, the genetic code has been used to predict protein sequences from DNA and mRNA sequences. Our @nature.com article demonstrates that these predictions miss thousands of protein sequences present in human tissues. www.nature.com/articles/s41... 1/

Bild
Nikolai Slavov@slavov-n.bsky.social · 2y ago

We report many proteins not predicted by the genetic code. They are stable & abundant O( 10³ ) copies / cell. Generative mechanisms include codon-anticodon mismatches & RNA modifications. Their abundance depends on codon frequency & protein stability. www.biorxiv.org/content/10.1...

John Ebos@ebos.bsky.social · 3mo ago

Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response

Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response

AbstractMultiplexed imaging of tissues is an approach that holds promise for improving early detection, diagnosis, and treatment of cancer. In this study, we investigated multiplexed histologic images...

aacrjournals.org

Nature@nature.com · 6mo ago

Nature research paper: The integrated stress response promotes immune evasion through lipocalin 2 go.nature.com/3MR7cQv

The integrated stress response promotes immune evasion through lipocalin 2 - Nature

The transcription factor ATF4 and its effector lipocalin 2 (LCN2) have a key role in immune evasion and tumour progression, and targeting the ATF4–LCN2 axis might provide a way to treat several types of solid tumour by increasing anti-cancer immunity.

go.nature.com

Mike Feigin 🥯@mikefeigin.bsky.social · 4mo ago

New FeiginLab paper is OUT! A commonly prescribed anti-anxiety drug reduces inflammatory signaling in pancreatic cancer through regulation of cancer-associated fibroblast activity! aacrjournals.org/cancerrescom...

Alprazolam reduces inflammatory cytokine production in pancreatic cancer-associated fibroblasts

Abstract. Pancreatic ductal adenocarcinoma (PDAC) diagnoses are often accompanied by a number of physical and psychological symptoms, including anxiety and depression. As a result, many patients are p...

aacrjournals.org

Nature Portfolio@natureportfolio.nature.com · 4mo ago

Repeated cloning cannot be sustained indefinitely in mammals, according to a 20-year study in mice published in Nature Communications. The results suggest that sexual reproduction is necessary to eliminate large-scale genetic mutations that can accumulate in mammalian clones. 🧬 🧪

Limitations of serial cloning in mammals - Nature Communications

Here they show that extended serial somatic cell cloning imposes a threefold increase in de novo mutations compared to natural reproduction, progressively reducing birth rates and ultimately limiting clonal propagation to 58 generations.

go.nature.com

OncLive@onclive.bsky.social · 5mo ago

WATCH: Emese Zsiros, MD, PhD, FACOG, of @roswellpark.bsky.social, discusses the @fda.gov approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer. #gyncsm #oncology www.onclive.com/view/dr-zsir...

Dr Zsiros on the Use of Pembrolizumab/Paclitaxel/Bevacizumab for Ovarian Cancer | OncLive

Emese Zsiros, MD, PhD, FACOG, discusses the FDA approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer.

onclive.com

Cancer Cell@cp-cancercell.bsky.social · 5mo ago

AI for cancer treatment information: Can academia stay in the game?

AI for cancer treatment information: Can academia stay in the game?

In this issue of Cancer Cell, Jun et al. developed a retrieval-augmented large language model linked to an academia-led molecular knowledge database, demonstrating how AI may deliver cancer treatment information without hallucination. It must compete for adoption amid a fast-paced, industry-led transformation in the flow of clinical information to patients.

dlvr.it

John Ebos@ebos.bsky.social · 5mo ago

Thank you to the Sinclair Cancer Research Institute at Queens University for hosting my visit this week. It was fantastic to share our science from Roswell Park and to meet with so many investigators and trainees. @sinclaircri.bsky.social @queensuresearch.bsky.social @roswellpark.bsky.social

Sinclair Cancer Research Institute@sinclaircri.bsky.social · 6mo ago

Coming soon! Dr. Ebos @ebos.bsky.social will be presenting in our @sinclaircri.bsky.social seminar series on Feb 26 at 4 PM. Questions? Send us an email: scri@queensu.ca #ResearchTalk #SeminarAlert #CancerResearch #CancerDrugResistance @queensuhealth.bsky.social @queensuresearch.bsky.social

NEJM.org@nejm.org · 7mo ago

In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg

The New England Journal of Medicine ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer A Research Summary based on Powles T et al. | 10.1056/NEJMoa2511885 | Published on October 20, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
Hannah R. Abrams@hannahrabrams.bsky.social · 8mo ago

🌅 Several studies have suggested checkpoint inhibitors dosed AM may be assoc w/ improved outcomes- but strong risk of confounding. Out now in #JCOOP: review of literature & discussion of how practices could actually implement this. Suspect will be very dependent on local AM traffic!

Fig 2. Constraints related to the patient, the pharmacy, and the outpatient infusion centers to be taken into account when concentrating outpatient ICI administrations in a stipulated time window in the morning. ICI, immune checkpoint inhibitor. Pharmacy constraints: physiochemical stability, risk of waste. Patient: distance home-hospital, diurnal preference. Day unit: priority rankings, long multi drug regimens.Proposed Action We propose the following approaches to make early ToDA of ICI feasible in daily routine practice: • ASSESS: establish a nurse-led telephone assessment on the eve of ICI administration with full blood work-up available to confirm clinical and biologic permissiveness to ICI treatment; • AVOID (as far as possible and according to the habits of each center): do not schedule medical consultation and ICI treatment on the same day to reduce risks of delays in treatment administration (prefer teleconsultations the day before treatment for patients living far from the center); • ALWAYS administer ICI first when in combination with IV chemotherapy or other agents, unless reverse sequencing is recommended; • ALLOCATE: prioritize two or three ICI mornings per week and save the remaining two or three mornings for long-term combination treatments not including ICIs; • ANTICIPATE: whenever possible, cytotoxic reconstruction units could prepare ICIs in the evening of the eve so that they are ready to be administered early on the following morning.